Singular Genomics Systems, Inc. Common Stock
OMIC
OMIC was delisted on the 20th of February, 2025.
52 hedge funds and large institutions have $757M invested in Singular Genomics Systems, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 52 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
38.87% more ownership
Funds ownership: 0% → 38.87% (+39%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$235M |
| 2 |
PA
Perceptive Advisors
New York
|
+$79.6M |
| 3 |
CC
Casdin Capital
New York
|
+$69.6M |
| 4 |
Coatue Management
New York
|
+$54.8M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$54.8M |
Top Sellers
OMIC Hedge Fund Activity: Q2 2021 in Review
52 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Singular Genomics Systems, Inc. Common Stock (OMIC) for Q2 2021, worth a combined $757M.
Buyers outnumbered sellers: 52 funds opened new OMIC positions and 0 closed out — a net gain of 52 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $235M.
- 52 institutional investors held Singular Genomics Systems, Inc. Common Stock (OMIC) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $757M of Singular Genomics Systems, Inc. Common Stock stock for Q2 2021.
- 52 funds opened new Singular Genomics Systems, Inc. Common Stock positions in Q2 2021 and 0 closed out, a net change of +52 holders.
- The largest Singular Genomics Systems, Inc. Common Stock buyer in Q2 2021 was Deerfield Management, an estimated $235M added.
Based on aggregated 13F filings for Q2 2021.